- What We’ve Accomplished
- Our Current Focus
- Looking Ahead
What We’ve Accomplished
As a leader and pioneer in antiviral development, we helped transform HIV from a fatal illness to a preventable chronic condition. We introduced the first HIV single tablet treatment regimen and continue to improve safety, convenience and efficacy in treatment and prevention options. In hepatitis, we developed a cure for hepatitis C, and our therapies helped transform hepatitis B into a more manageable condition. And when the world needed us, we stepped up to deliver the first approved antiviral medicine to treat COVID-19.
These advances were possible thanks to our investment in world-class science, our deep connections with community partners and our long-standing commitment to expanding health equity.
Our Current Focus
Today, we’re building on our legacy in virology, developing long-acting options for HIV prevention and treatment while working together with community partners to help end the epidemic. At the same time, we're developing new treatments for chronic hepatitis B and D as we work toward the global elimination of hepatitis.
Looking Ahead
We won’t rest until the HIV epidemic has ended for everyone, everywhere. Ultimately, we're working to help develop cures for HIV and hepatitis B, while advancing our preparedness against potential infectious diseases.
At the same time, we recognize that medicines alone won’t lead to the healthier world we envision. We’re committed to working closely with partners to advance health equity and break down the barriers to care that fuel the spread of viruses and affect access to care.
PIPELINE
We have a strong, diverse pipeline and are on track to achieve our 2019 ambition of delivering 10+ transformative therapies by 2030.
Explore Our Pipeline
Clinical Trials
We're committed to involving the communities most impacted by disease in the design and execution of our clinical trials.
Medicines
We currently offer more than 25 therapies in the United States and are rapidly growing our portfolio through internal research and development and external collaborations.
Latest News
Some of the content on this page is not intended for users outside the U.S.